Quality of bevacizumab compounded for intravitreal administration

Eye (Basingstoke)

Volumn 27, Issue 9, 2013, Pages 1090-1097

  Palmer, J M ^a   Amoaku, W M ^b   Kamali, F ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Avastin; Bevacizumab; Compounding; Storage

Indexed keywords

BEVACIZUMAB; IMMUNOGLOBULIN G;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DENSITY; DIGITAL FILTERING; DRUG PACKAGING; DRUG QUALITY; DRUG STABILITY; GEL PERMEATION CHROMATOGRAPHY; MOLECULAR WEIGHT; PARTICLE SIZE; PHARMACY; POLYACRYLAMIDE GEL ELECTROPHORESIS; SYRINGE; UNITED KINGDOM;

EID: 84883749359     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2013.139     Document Type: Article

References (35)

1. Genentech. Avastin. Summary of product characteristics. January 2010. Available at http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR--- Product- Information/human/000582/WC500029271.pdf. (accessed July 2012
2. Novartis. Lucentis summary of product characteristics. January 2012. Available at http://www.medicines.org.uk/ emc/history/19409/SPC/Lucentis10mgml solutionorinjection. (accessed July 2012
3. Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn Jr, HW et al. Short-Term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular agerelated macular degeneration. Retina 2006; 26: 495-511
4. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-1908
5. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration. Ophthalmology 2012; 119: 1399-1411
6. Jyothi S, Chowdhury H, Elagouz M, Sivaprasad S. Intravitreal bevacizumab (Avastin) for age-related macular degeneration: A critical analysis of literature. Eye 2009; 24: 816-824
7. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006; 26: 257-261
8. Chang TS, Kokame G, Casey R, Prenner J, Feiner L, Anderson N. Short-Term effectiveness of intravitreal bevacizumab versus ranibizumab injections for patients with neovascular age-related macular degeneration. Retina 2009; 29: 1235-1241
9. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results. Ophthalmology 2012; 119: 1388-1398
10. Bakri SJ, Larson TA, Edwards AO. Intraocular inflammation following intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol 2008; 246: 779-781
11. Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H. Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection. Eye 2009; 23: 2187-2193
12. Yamashiro K, Tsujikawa A, Miyamoto K, Oh H, Otani A, Tamuara H et al. Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch. Retina 2010; 30: 485-490
13. Kay CN, Tarantola RM, Gehrs KM, Folk JC, Mahajan VB, Boldt HC et al. Uveitis following intravitreal bevacizumab: A non-infectious cluster. Ophthalmic Surg Lasers Imaging 2011; 42: 292-296
14. Ness T, Feltgen N, Agostini H, Bohringer D, Lubrich B. Toxic vitreitis outbreak after intravitreal injection. Retina 2010; 30: 332-338
15. Medicines and Healthcare products Regulatory Agency 2012, Company-led drug recall: Bevacizumab Intravitreal Injection 1.25mg/0.05ml-Moorfields Pharmaceuticals-CLDA(12)A/04 http://www.mhra.gov.uk/ Safetyinformation/ Safetywarningsalertsandrecalls/ DrugAlerts/Company-ledrecalls/CON146660. (accessed 15 March
16. Goldberg RA, Flynn Jr., HW, Isom RF, Miller D, Gonzalez S. An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab. Am J Ophthalmol 2012; 153: 204-208; e1
17. Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 2011; 95: 1111-1114
18. Jalil A, Fenerty C, Charles S. Intravitreal bevacizumab (Avastin) causing acute glaucoma: An unreported complication. Eye 2007; 21: 1541
19. Kahook MY, Kimura AE, Wong LJ, Ammar DA, Maycotte MA, Mandava N. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging 2009; 40: 293-295
20. Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther 2010; 26: 105-110
21. Choi DY, Ortube MC, McCannel CA, Sarraf D, Hubschman JP, McCannel TA et al. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib. Retina 2011; 31: 1028-1035
22. Liu L, Ammar DA, Ross L, Mandava N, Kahook M, Carpenter J. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: Effects of long-Term storage and product mishandling. Invest Ophthalmol Vis Sci 2011; 52: 1023-1034
23. Kahook MY, Liu L, Ruzycki P, Mandava N, Carpenter JF, Petrash JM et al. High-molecular-weight aggregates in repackaged bevacizumab. Retina 2010; 30: 887-892
24. Particulate Matter in Injections, USP 28/NF 23, Chapter 788, United States Pharmacopeial Convention, Inc: Rockville, MD, 2005
25. Costa R. Particulate Matter in Ophthalmic Solutions, USP 28/NF 23, Chapter 789, United States Pharmacopeial Convention, Inc.: Rockville, MD, 2005
26. Weber AJ, Zelenak D. Experimental glaucoma in the primate induced by latex microspheres. J Neurosci Methods 2001; 111: 39-48
27. Urcola JH, Hernandez M, Vecino E. Three experimental glaucoma models in rats: Comparison of the effects of intraocular pressure elevation on retinal ganglion cell size and death. Exp Eye Res 2006; 83: 429-437
28. Quigley HA, Addicks EM. Chronic experimental glaucoma in primates. I. Production of elevated intraocular pressure by anterior chamber injection of autologous ghost red blood cells. Invest Ophthalmol Vis Sci 1980; 19: 126-136
29. Bakri SJ, Snyder MR, Pulido JS, McCannel CA, Weiss WT, Singh RJ. Six-month stability of bevacizumab (Avastin)binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing. Retina 2006; 26: 519-522
30. Strehl R, Rombach-Riegraf V, Diez M, Egodage K, Bluemel M, Jeschke M et al. Discrimination between silicone oil droplets and protein aggregates in biopharmaceuticals: A novel multiparametric image filter for sub-visible particles in microflow imaging analysis. Pharm Res 2012; 29: 594-602
31. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254
32. Laemmli UK, Favre M. Maturation of the head of bacteriophage T4. I. DNA packaging events. J Mol Biol 1973; 80: 575-599
33. FDA alerts health care professionals of infection risk from repackaged Avastin intravitreal injections. 30 August 2011 http://www.fda.gov/Drugs/ DrugSafety/ucm270296.htm. (accessed July 2012
34. Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJ, Middaugh CR, Winter G et al. Overlooking subvisible particles in therapeutic protein products: Gaps that may compromise product quality. J Pharm Sci 2009; 98: 1201-1205
35. Paul M, Vieillard V, Roumi E, Cauvin A, Despiau MC, Laurent M et al. Long-Term stability of bevacizumab repackaged in 1mL polypropylene syringes for intravitreal administration. Ann Pharm Fr 2012; 70: 139-154